Results 111 to 120 of about 932,600 (248)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. [PDF]

ESMO Open, 2023
Cufer T, Kosty MP, Curriculum Development Subgroup—ESMO/ASCO Global Curriculum Working Group.   +2 more
europepmc   +2 more sources

Scientific Meetings in Medical Oncology: Are We Facing a Time- and Resource-Consuming Plethora? [PDF]

Curr Oncol
Gebbia V, Piazza D, Scrima F, Passanisi A, Sambataro D, Scandurra G, Valerio MR.   +6 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

European Society for Medical Oncology (ESMO) congress 2025. [PDF]

Lancet Reg Health Eur
Nedic I.
europepmc   +1 more source

Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology-A National Questionnaire. [PDF]

Curr Oncol, 2023
Febbraro M, Kazemi G, Juergens R, Pond GR.   +3 more
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Nutritional Risk in Patients Admitted to Medical Oncology Departments: Prevalence, Associated Factors and Clinical Outcomes in a Multicentre Prospective Study. [PDF]

Nutrients
Teigell Muñoz FJ, Llobera Rius L, Medina Ortega L, Villacé Gallego P, Marco-Hernández J, Fernández Fernández EP, Esquerrà Molas A, Liesa Delgado L, Sáez Urán LM, González Olmedo J, Heredia-Mena C, Romero Hernández J, Llaberia-Torrelles M, Delgado Heredia MJ, Bazaga Rodas N, Fernández-Cordón L, Macía-Rodríguez C, Soldado J, García-Villa A.   +18 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Radiation and Medical Oncology Perspectives on Oligometastatic Disease Treatment. [PDF]

Fed Pract
Wallach JB, Malhotra S, Lee SP, Hoffman-Hogg L, Shapiro R, Wechsler G, Faricy-Anderson K, McGunigal MC, Kelly MD, Gutt R.   +9 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source